Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 4 · 50%High 2 · 25%

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease‐specific quality of life · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Disease severity ‐ VAS (range 0 to 10, lower = better) · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Serious adverse events · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) may leads to lower serious adverse events compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.47 [0.29, 0.76]
3 studies · 782 participants
Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.17 [0.05, 0.52]
2 studies · 725 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Extent of disease ‐ endoscopic score · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Extent of disease ‐ CT scan (lower score = better) · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 784 participants
High

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Generic quality of life measures · patients with severe chronic rhinosinusitis with nasal polyps

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 766 participants
Moderate

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
RR 0.95 [0.72, 1.25]
3 studies · 783 participants
Low